Syndax Pharmaceuticals Overview
Valuation check: SNDX's P/E ratio is -6.99, below the Healthcare sector average of 25.3.
Get informed when a big investor buys or sells
+ Follow-6.99
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Syndax Pharmaceuticals (SNDX) currently reports a P/E ratio of -6.99. That is below the Healthcare sector average of 25.3. Use the charts on this page to explore Syndax Pharmaceuticals's P/E ratio history and peer comparisons.
Syndax Pharmaceuticals's P/E ratio of -6.99 is lower than the Healthcare sector average of 25.3. That is roughly 127.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Syndax Pharmaceuticals's market price to a fundamental measure such as earnings, sales, or book value. At -6.99, SNDX can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -6.99, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 25.3. From there, open related valuation or income-statement pages for Syndax Pharmaceuticals, and consider following SNDX for alerts when major investors trade the stock.
Syndax Pharmaceuticals is classified in the Healthcare sector. On P/E ratio, it currently shows -6.99 versus a sector average near 25.3. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SNDX with unrelated industries.
